Market Newsdesk

• Continued progress for AFM13 and AFM24 clinical studies
• Strengthened cash position provides anticipated runway into the first half of 2023

Heidelberg, Germany, January 7, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an update on its pipeline and business.

“Affimed ended 2020 with significant momentum across all major programs and a strong balance sheet that provides cash runway into the first half of 2023,” commented CEO Adi Hoess. “With three innate cell engagers in clinical development and multiple active collaborations, Affimed is positioned for numerous catalysts in 2021 and beyond.”

Clinical Stage Program Updates

AFM13 (CD30/CD16A ICE®)

• AFM13-202, a Phase 2 registration-directed study of AFM13 as monotherapy in relapsed or refractory patients with CD30-positive peripheral T-cell lymphoma (pTCL), remains ahead of schedule and Affimed expects to complete the interim data analysis during the first half of 2021.
• The first dose cohort of AFM13-104, an investigator sponsored Phase 1 study at The University of Texas MD Anderson Cancer Center evaluating the tolerability and efficacy of AFM13 preloaded cord blood-derived NK cells (cbNK) followed by weekly AFM13 monotherapy in patients with refractory CD30 expressing lymphomas, is ongoing.

AFM24 (EGFR/CD16A ICE®)

• AFM24-101, a Phase 1/2a clinical trial of AFM24, the EGFR/CD16A targeted ICE® for treatment of patients with EGFR-expressing solid tumors, has completed dose cohort 3 (80 mg per patient) without showing dose limiting side effects and patients are currently being enrolled and treated in dose cohort 4 (160 mg per patient).
• Affimed and NKMax America completed a pre-IND meeting with the U.S. Food and Drug Administration in December 2020.  The companies plan to submit an IND in the first half of 2021 for a Phase1/2a study to investigate different dose levels of AFM24 in combination with NKMax America`s autologous NK cell product SNK01 in patients with EGFR expressing solid tumors.

Other Business Updates

• As of December 31, 2020, Affimed’s preliminary unaudited cash and cash equivalents were approximately €147 million. Based on its current operating plan and assumptions, Affimed anticipates that its cash and cash equivalents will support operations into the first half of 2023.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

FORWARD-LOOKING STATEMENTS

 This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of our ICE® molecules, the value of our ROCK® platform, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our collaboration activities, our ability to develop commercial functions, clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation and the risks, uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Investor Relations Contact

Alexander Fudukidis
Head of Investor Relations
E-Mail: [email protected]
Tel.: +1 (917) 436-8102

Media Contact

Mary Beth Sandin
Head of Marketing and Communications
E-Mail: [email protected]

NEWTON, Kansas, Jan. 07, 2021 (GLOBE NEWSWIRE) — Park Aerospace Corp. (NYSE-PKE) reported results for the 2021 fiscal year third quarter ended November 29, 2020. As previously reported, Park completed the sale of its Electronics Business to AGC Inc. on December 4, 2018. Therefore, current costs relating to the Electronics Business are reported as discontinued operations. Continuing operations discussed below refer to Park’s Aerospace Business unless otherwise indicated.

The Company will conduct a conference call to discuss its financial results and other matters at 11:00 a.m. EST today. A live audio webcast of the event, along with presentation materials, will be available at https://edge.media-server.com/mmc/p/fpex6v6n at 11:00 a.m. EST today. The presentation materials will also be available at approximately 9:00 a.m. EST today at https://parkaerospace.com/shareholders/investor-conference-calls/ and on the Company’s website at www.parkaerospace.com under “Investor Conference Calls” on the “Shareholders” page.

Continuing Operations:

Park reported net sales of $10,372,000 for the 2021 fiscal year third quarter ended November 29, 2020 compared to $15,847,000 for the 2020 fiscal year third quarter ended December 1, 2019 and $9,250,000 for the 2021 fiscal year second quarter ended August 30, 2020.  Park’s net sales from continuing operations for the nine months ended November 29, 2020 were $31,835,000 compared to $44,520,000 for the nine months ended December 1, 2019. Net earnings from continuing operations for the 2021 fiscal year third quarter were $1,037,000 compared to $2,806,000 for the 2020 fiscal year third quarter and $1,151,000 for the 2021 fiscal year second quarter. Net earnings from continuing operations were $4,160,000 for the current year’s first nine months compared to $7,572,000 for last year’s first nine months.

EBITDA from continuing operations for the 2021 fiscal year third quarter was $1,380,000 compared to $3,622,000 for the 2020 fiscal year third quarter and $1,418,000 for the 2021 fiscal year second quarter.

For the nine months ended November 29, 2020, Park reported net earnings from continuing operations before special items of $4,160,000 compared to $7,716,000 for last fiscal year’s first nine months.  In the 2020 fiscal year’s first nine months, the Company recorded a one-time tax charge of $144,000 for the write down of deferred tax assets for stock option expirations pertaining to employees who transferred to AGC Inc. in connection with the sale of the Electronics Business. EBITDA from continuing operations for the current year’s first nine months was $5,162,000 compared to $9,400,000 for last year’s first nine months.

Park reported basic and diluted earnings per share from continuing operations of $0.05 for the 2021 fiscal year third quarter compared to $0.14 for the 2020 fiscal year third quarter and $0.06 for the 2021 fiscal year second quarter.

Park reported basic and diluted earnings per share from continuing operations of $0.20 for the 2021 fiscal year’s first nine months compared to $0.37 for the 2020 fiscal year’s first nine months. Basic and diluted earnings per share from continuing operations before special items were $0.20 for the 2021 fiscal year’s first nine months compared to basic earnings per share from continuing operations before special items of $0.38 and diluted earnings per share from continuing operations before special items of $0.37 for the 2020 fiscal year’s first nine months. 

The Company will conduct a conference call to discuss its financial results at 11:00 a.m. EST today.  Forward-looking and other material information may be discussed in this conference call.  The conference call dial-in number is (844) 466-4114 in the United States and Canada, and (765) 507-2654 in other countries.  The required passcode for attendance by phone is 4883755.

For those unable to listen to the call live, a conference call replay will be available from approximately 2:00 p.m. EST today through 11:59 p.m. EST on Wednesday, January 13, 2021.  The conference call replay will be available at https://edge.media-server.com/mmc/p/fpex6v6n and on the Company’s website at www.parkaerospace.com under “Investor Conference Calls” on the “Shareholders” page.  It can also be accessed by dialing (855) 859-2056 in the United States and Canada, and (404) 537-3406 in other countries. The required passcode for accessing the replay by phone is 4883755. 

Any additional material financial or statistical data disclosed in the conference call, including the investor presentation, will also be available at the time of the conference call on the Company’s web site at
https://parkaerospace.com/shareholders/investor-conference-calls/.

Park believes that an evaluation of its ongoing operations would be difficult if the disclosure of its operating results were limited to accounting principles generally accepted in the United States of America (“GAAP”) financial measures, which include special items, such as a one-time tax charge and EBITDA. Accordingly, in addition to disclosing its operating results determined in accordance with GAAP, Park discloses non-GAAP measures, including EBITDA, and operating results that exclude special items in order to assist its shareholders and other readers in assessing the Company’s operating performance, since the Company’s on-going, normal business operations do not include such special items. The detailed operating information presented below includes a reconciliation of the non-GAAP operating results before special items to earnings determined in accordance with GAAP and a reconciliation of GAAP pre-tax earnings to EBITDA. Such non-GAAP financial measures are provided to supplement the results provided in accordance with GAAP.

Park Aerospace Corp. develops and manufactures solution and hot-melt advanced composite materials used to produce composite structures for the global aerospace markets. These materials include lightning strike protection materials. Park offers an array of composite materials specifically designed for hand lay-up or automated fiber placement (AFP) manufacturing applications.  Park’s advanced composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as “drones”), business jets, general aviation aircraft and rotary wing aircraft.  Park also offers specialty ablative materials for rocket motors and nozzles and specially designed materials for radome applications.  As a complement to Park’s advanced composite materials offering, Park designs and fabricates composite parts, structures and assemblies and low volume tooling for the aerospace industry. Target markets for Park’s composite parts and structures (which include Park’s proprietary composite SigmaStrut™ and AlphaStrut™ product lines) are, among others, prototype and development aircraft, special mission aircraft, spares for legacy military and civilian aircraft and exotic spacecraft.  Park’s objective is to do what others are either unwilling or unable to do.  When nobody else wants to do it because it is too difficult, too small or too annoying, sign us up. 

Additional corporate information is available on the Company’s web site at www.parkaerospace.com

Performance table, including non-GAAP information (in thousands, except per share amounts –unaudited):

	13 Weeks Ended														39 Weeks Ended
	November 29, 2020					December 1, 2019					August 30, 2020				November 29, 2020					December 1, 2019
Sales	$	10,372				$	15,847				$	9,250			$	31,835				$	44,520
Net Earnings before Special Items1	$	1,037				$	2,806				$	1,151			$	4,160				$	7,716
Special Items, Net of Tax:
Tax Impact of Cancelled Stock Options	–					–					–				–					(144		)
Net Earnings from Continuing Operations	$	1,037				$	2,806				$	1,151			$	4,160				$	7,572
Loss from Discontinued Operations, Net of Tax	$	(116	)			$	(360	)			$	(197	)		$	(328	)			$	(404	)
Net Earnings	$	921				$	2,446				$	954			$	3,832				$	7,168
Basic Earnings per Share:
Basic Earnings before Special Items1	$	0.05				$	0.14				$	0.06			$	0.20				$	0.38
Special Items:
Tax Impact of Cancelled Stock Options	–					–					–				–					(0.01		)
Basic Earnings per Share from Continuing Operations	$	0.05				$	0.14				$	0.06			$	0.20				$	0.37
Basic Loss per Share from Discontinued Operations	–					(0.02		)			(0.01		)		(0.01		)			(0.02		)
Basic Earnings per Share	$	0.05				$	0.12				$	0.05			$	0.19				$	0.35
Diluted Earnings before Special Items1	$	0.05				$	0.14				$	0.06			$	0.20				$	0.37
Special Items:
Tax Impact of Cancelled Stock Options	–					–					–				–					–
Diluted Earnings per Share from Continuing Operations	$	0.05				$	0.14				$	0.06			$	0.20				$	0.37
Diluted Loss per Share from Discontinued Operations	–					(0.02		)			(0.01		)		(0.01		)			(0.02		)
Diluted Earnings per Share	$	0.05				$	0.12				$	0.05			$	0.19				$	0.35
Weighted Average Shares Outstanding:
Basic	20,381					20,518					20,381				20,388					20,503
Diluted	20,434					20,617					20,433				20,442					20,601
1 Refer to “Reconciliation of non-GAAP financial measures” below for information regarding Special Items.

 

Comparative balance sheets (in thousands):

	November 29, 2020				March 1, 2020
Assets	(unaudited)
Current Assets
Cash and Marketable Securities	$	116,966			$	122,355
Accounts Receivable, Net	8,372				10,925
Inventories	4,712				6,379
Prepaid Expenses and Other Current Assets	3,842				5,535
Total Current Assets	133,892				145,194
Fixed Assets, Net	20,481				16,100
Operating Right-of-use Assets	304				420
Other Assets	9,959				10,072
Total Assets	$	164,636			$	171,786
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts Payable	$	3,338			$	4,735
Accrued Liabilities	1,510				1,709
Operating Lease Liability	113				152
Income Taxes Payable	2,242				2,111
Total Current Liabilities	7,203				8,707
Long-term Operating Lease Liability	206				268
Non-current Income Taxes Payable	14,303				15,986
Deferred Income Taxes	953				834
Other Liabilities	4,476				4,316
Total Liabilities	27,141				30,111
Shareholders’ Equity	137,495				141,675
Total Liabilities and Shareholders’ Equity	$	164,636			$	171,786
Additional information
Equity per Share	$	6.75			$	6.90

 

Comparative statements of operations (in thousands – unaudited):

	13 Weeks Ended															39 Weeks Ended
	November 29, 2020					December 1, 2019					August 30, 2020					November 29, 2020					December 1, 2019
Net Sales	$	10,372				$	15,847				$	9,250				$	31,835				$	44,520
Cost of Sales	7,819					10,825					6,612					22,970					30,881
Gross Profit	2,553					5,022					2,638					8,865					13,639
% of net sales	24.6		%			31.7		%			28.5		%			27.8		%			30.6		%
Selling, General & Administrative Expenses	1,536					1,949					1,552					4,718					5,785
% of net sales	14.8		%			12.3		%			16.8		%			14.8		%			13.0		%
Earnings from Continuing Operations	1,017					3,073					1,086					4,147					7,854
Interest and Other Income:
Interest Income	389					802					525					1,570					2,613
% of net sales	3.8		%			5.1		%			5.7		%			4.9		%			5.9		%
Earnings from Continuing Operations before Income Taxes	1,406					3,875					1,611					5,717					10,467
Income Tax Provision	369					1,069					460					1,557					2,895
Net Earnings from Continuing Operations	1,037					2,806					1,151					4,160					7,572
% of net sales	10.0		%			17.7		%			12.4		%			13.1		%			17.0		%
Loss from Discontinued Operations, Net of Tax	(116		)			(360		)			(197		)			(328		)			(404		)
Net Earnings	$	921				$	2,446				$	954				$	3,832				$	7,168
% of net sales	8.9		%			15.4		%			10.3		%			12.0		%			16.1		%

 

Reconciliation of non-GAAP financial measures (in thousands – unaudited):

	13 Weeks Ended November 29, 2020									13 Weeks Ended December 1, 2019									13 Weeks Ended August 30, 2020
	GAAP			Specials Items		Before Special Items				GAAP			Specials Items		Before Special Items				GAAP			Specials Items		Before Special Items
Earnings from Continuing Operations	1,017			–		1,017				3,073			–		3,073				1,086			–		1,086
% of net sales	9.8	%				9.8	%			19.4	%				19.4	%			11.7	%				11.7	%
Interest Income	389			–		389				802			–		802				525			–		525
% of net sales	3.8	%				3.8	%			5.1	%				5.1	%			5.7	%				5.7	%
Earnings from Continuing Operations before Income Taxes	1,406			–		1,406				3,875			–		3,875				1,611			–		1,611
% of net sales	13.6	%				13.6	%			24.5	%				24.5	%			17.4	%				17.4	%
Income Tax Provision	369			–		369				1,069			–		1,069				460			–		460
Effective Tax Rate	26.2	%				26.2	%			27.6	%				27.6	%			28.6	%				28.6	%
Net Earnings from Continuing Operations	1,037			–		1,037				2,806			–		2,806				1,151			–		1,151
% of net sales	10.0	%				10.0	%			17.7	%				17.7	%			12.4	%				12.4	%
Loss from Discontinued Operations	(116	)		–		(116	)			(360	)		–		(360	)			(197	)		–		(197	)
% of net sales	-1.1	%				-1.1	%			-2.3	%				-2.3	%			-2.1	%				-2.1	%
Net Earnings	921			–		921				2,446			–		2,446				954			–		954
% of net sales	8.9	%				8.9	%			15.4	%				15.4	%			10.3	%				10.3	%
Earnings from Continuing Operations						1,017									3,073									1,086
Addback non-cash expenses:
Depreciation						314									410									282
Stock Option Expense						49									139									50
EBITDA						1,380									3,622									1,418

 

Reconciliation of non-GAAP financial measures – continued (in thousands – unaudited):

	39 Weeks Ended November 29, 2020									39 Weeks Ended December 1, 2019
	GAAP			Specials Items		Before Special Items				GAAP			Specials Items			Before Special Items
Earnings from Continuing Operations	4,147			–		4,147				7,854			–			7,854
% of net sales	13.0	%				13.0	%			17.6	%					17.6	%
Interest Income	1,570			–		1,570				2,613			–			2,613
% of net sales	4.9	%				4.9	%			5.9	%					5.9	%
Earnings from Continuing Operations before Income Taxes	5,717			–		5,717				10,467			–			10,467
% of net sales	18.0	%				18.0	%			23.5	%					23.5	%
Income Tax Provision	1,557			–		1,557				2,895			(144	)		2,751
Effective Tax Rate	27.2	%				27.2	%			27.7	%					26.3	%
Net Earnings from Continuing Operations	4,160			–		4,160				7,572			144			7,716
% of net sales	13.1	%				13.1	%			17.0	%					17.3	%
Loss from Discontinued Operations	(328	)		–		(328	)			(404	)		–			(404	)
% of net sales	-1.0	%				-1.0	%			-0.9	%					-0.9	%
Net Earnings	3,832			–		3,832				7,168			144			7,312
% of net sales	12.0	%				12.0	%			16.1	%					16.4	%
Earnings from Operations						4,147										7,854
Addback non-cash expenses:
Depreciation						873										1,142
Stock Option Expense						142										404
EBITDA						5,162										9,400

 

Contact:	Donna D’Amico-Annitto	486 North Oliver Road, Bldg. Z
		Newton, Kansas 67114
		(316) 283-6500

 

BEIJING, Jan. 07, 2021 (GLOBE NEWSWIRE) — ZW Data Action Technologies, Inc. (Nasdaq: CNET) (“ZW Data” or the “Company”), an integrated online advertising, precision marketing, data analytics, and other value-added services company, today announced that it has reached strategic partnership with Yujun Capital and its subsidiary Yujun Digital Technology Co., Ltd. (together, “Yujun Digital”) pursuant to which Yujun Digital will provide online branding and management service to the Company’s merchant clients.

Yujun Digital team consists of experts in the fields of new consumer products and digital transformation in the Guangdong-Hong Kong-Macao Greater Bay Area. The team members include a Ph.D. in international economic relations, a former Tencent product director, former Tmall senior operation experts, and senior content marketing experts from MCN agencies. ZW Data believes that Yujun Digital’s capabilities dovetail well with the Company’s blockchain technology, big data platform, supply chain management capabilities, and private domain traffic operation capabilities. The Company is confident that together they will build a strong management and consumer service platform for its merchant clients.

Building on its earlier success of creating distributed communities and distributed private domains covering 2,700 counties across the country, tens of millions of Internet 2C users, and 100,000 E-commerce brands, the Company believes that the strategic partnership with Yujun Capital and Yujun Digital will enable them to build bigger communities for new consumption branding industry.

Handong Cheng, Chairman and Chief Executive Officer of ZW Data, commented, “ZW Data and Yujun Capital will build a five-dimensional platform with digital product selection, brand content marketing, digital growth, private domain traffic operation, and brand digital intelligence. Through integration of capital, strategy, brand, private domain, data and intelligent solutions, we strive to assist our clients in their brand building with blockchain technology. In particular, we hope to promote growth of national brands in the post-pandemic era when China’s economic policy shifts to domestic consumption.”

About ZW Data Action Technologies Inc.

Established in 2003 and headquartered in Beijing, China, ZW Data Action Technologies Inc. (the “Company”) offers online advertising, precision marketing, data analytics and other value-added services for enterprise clients. Leveraging its fully integrated services platform, proprietary database, and cutting-edge algorithms, ZW Data Action Technologies delivers customized, result-driven business solutions for small and medium-sized enterprise clients in China. The Company also develops blockchain and artificial intelligence enabled web/mobile applications and software solutions for general public, enterprise clients, and government agencies. More information about the Company can be found at: http://www.zdat.com/.

About Yujun Capital

Yujun Capital was established in 2007. It provides private equity fund management and services with entrepreneurial spirit and is committed to creating high-quality venture capital. It focuses on the intrinsic value of its projects and strives to empower its business partners and accompany them in different development stages.

Yujun Capital integrates its years of operation experience, resources, and investment service capabilities to establish an industrial and capital ecosystem. Through its equity investment and capital market services, Yujun facilitates project development and bring value to the investors.

Yujun Capital provides targeted assistance to women entrepreneurs. It has been building business women communities and nurturing women entrepreneurs by setting up funds exclusively for investment in women-led projects.

In 2020, Yujun Capital established Yujun Digital Technology to cultivate general partners in its venture studios. It strives to create a leading investment fund in female consumption segments by working with Shenzhen Yuewan Digital Development Research Institute.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of ZW Data Action Technologies Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ZW Data Action Technologies current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting ZW Data Action Technologies will be those anticipated by ZW Data Action Technologies. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ZW Data Action Technologies undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

For more information, please contact:

Sherry Zheng
Weitian Group LLC
Email: [email protected]
Phone: +1 718-213-7386

Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019

Completion of European Regulatory Review and Submission of China Regulatory Application for VASCEPA^® (icosapent ethyl) Expected in Late January or February 2021

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2020 revenue results. Amarin plans to discuss these results and expectations with investors in connection with the 39th Annual J.P. Morgan Healthcare Conference at which Amarin is scheduled to present on Tuesday, January 12, 2020, at 2:00 pm Eastern time.

Preliminary (unaudited) 2020 Financial Results

Record Revenue Levels: Full-year 2020 total net revenue, subject to audit, are expected to be approximately $610 million. Despite the impact of COVID-19, this estimated 2020 net revenue expectation represents an increase of approximately 42% compared with full-year 2019 results. This growth was primarily driven by increased prescription levels of VASCEPA^® in the United States.

Liquid Assets: Amarin ended 2020 with more than $550 million in cash and investments, approximately $150 million in net accounts receivable and approximately $180 million in inventory.

No Debt: At year-end 2020, Amarin had no debt, having fully repaid its prior royalty-like debt instrument in the fourth quarter of 2020, which from 2013 through most of 2020 required approximately 10% of net revenue to be paid against this prior obligation.

Management Commentary

“Amarin has the people, product and resources to expand globally starting with anticipated 2021 VASCEPA regulatory approval and commercial launch in Europe. Our expected growth in Europe and elsewhere overseas will build on our growth and experience in the United States,” commented John F. Thero, president and chief executive officer. “We intend to build on our strong scientific foundation and medical experience. As patients begin to return for medical care beyond the COVID-19 era, we aim to ensure that VASCEPA is increasingly prescribed to help at-risk patients. While 2020 was a challenging year, I am thankful to our employees for the progress they made in countless areas. Their hard work and passion provide a strong foundation from which we will further launch VASCEPA to reduce persistent cardiovascular risk in appropriate patients, or P-CVR, in the United States, Europe and around the world.”

Highlights from 2020 and Outlook

U.S. Commercial

Amarin achieved a number of important commercial milestones in 2020, despite the challenges Amarin faced with COVID-19 and the November launch of generic icosapent ethyl in the United States.

U.S. commercial highlights from 2020 include:

• Record levels of VASCEPA revenues, prescriptions, prescribers and patients
• Faster prescription growth for VASCEPA as compared to most other cardiovascular drugs that reported positive outcomes studies in recent years, despite VASCEPA having a lower level of promotional spend than many such drugs
  • VASCEPA growth in 2020 due to COVID-19 was slower than initially expected but compares well with the growth in 2020 of peer drugs
• The P-CVR indication has quickly garnered the largest part of the market as approximately 93% of VASCEPA prescriptions based on the most recent data reported to us by IQVIA were for patients with triglyceride (TG) levels below 500 mg/dL
• Further expanded managed care coverage for VASCEPA during 2020 with additional improvements agreed for 2021
  • Such increases are consistent with third-party analysis, which found VASCEPA to be cost effective, and with medical guidelines or recommendations from six leading U.S. medical societies
• Doubled size of sales force (training for this expanded group was completed in March 2020 just before Amarin’s customer-facing team was temporarily prohibited from conducting in-person meetings due to COVID-19)
• Adapted to COVID-19 protocols with various tele-sales, tele-marketing and virtual education initiatives as well as training representatives to safely interact with healthcare professionals where possible

U.S. commercial outlook includes:

• Confidence that millions of at-risk patients remain untreated for P-CVR and could benefit from VASCEPA
• Recognition that many at-risk patients ceased doctor visits for ordinary care in 2020 but are likely to return to their doctors for needed care as COVID-19 risk recedes
  • According to IQVIA, patient visits to medical offices for non-emergency medical care were down approximately 70% in April 2020 during the height of COVID-19, with visits steadily increasing thereafter. In December 2020, as a result of a spike in COVID-19 cases, patient visits have decreased approximately 50% compared to pre-COVID levels
• Following a resurgence of COVID-19 in recent months, Amarin intends to reduce spending levels for certain forms of promotion (e.g., television advertisements) in early 2021
  • U.S. promotional spending likely to be variable with adjustments upward or downward in response to the changing impact from COVID-19 and generic competition
• As COVID-19 vaccine progress is made, along with other mitigating approaches, Amarin plans to increasingly resume its promotion of VASCEPA for P-CVR while continuing to adapt to market changes
  • Generic competition launched in November 2020 only for the original indication (TG >500 mg/dL) and is expected to continue to face supply limits, despite stockpiles of generic product likely created prior to launch
  • Variability is expected as patients, pharmacies and payers adjust to the availability, pricing and label of this generic competition
  • Due to the uncertainties regarding COVID-19 and potential generic supply, Amarin will continue to withhold 2021 revenue guidance for VASCEPA in the U.S. until there is greater clarity on the impact of these issues
• Amarin intends to continue to manage its U.S. commercial operations to expand patient care and enhance profits from U.S. operations

Europe

Europe highlights from 2020 include:

• Reached Day 180 of the European Medicines Agency, or EMA, centralized regulatory review of VASCEPA assuring that the United Kingdom is grandfathered into a facilitated review process despite its withdrawal from the European Union
• An expanded recommendation was issued by the European Society of Cardiology regarding use of icosapent ethyl (U.S. brand name VASCEPA)
• Increased the size of the Amarin team in Europe to approximately 50 experienced professionals to support pre-approval and pre-launch preparations for VASCEPA in select countries
• Commenced interactions with authorities in select countries regarding VASCEPA market access assuming approval, noting that more formal proceedings cannot progress until after the product is approved and the label is established
• Made major advances in expanding company-wide systems to support expected commercial launch of VASCEPA in Europe in 2021

Europe outlook includes:

• Millions of at-risk patients could benefit from VASCEPA in Europe
  • There are more patients on statins in Europe in aggregate compared to the U.S. and the rate of death from cardiovascular disease is higher
• Regulatory approval expected in early 2021
  • CHMP opinion expected in late January or February 2021
  • EMA approval decision expected within 67 days of CHMP decision
• Market access negotiations anticipated on a country-by-country basis promptly after approval
  • Seeking net pricing that equals or exceeds U.S. net pricing with focus on P-CVR indication based on outcomes data in Europe, whereas pricing in the U.S was based on original TG lowering indication
• Launch timing by country dependent on market access (i.e., insurance coverage)
  • At a minimum, launch expected in Germany in 2021 after initial product awareness campaign
  • Launch in Germany and other countries is anticipated to give priority to specialists (e.g., cardiologists) and to also include substantial digital educational and promotional initiatives
  • Target of approximately 200 employees (or contractors) in the European commercial team by end of 2021

Rest of World

Rest of world, or ROW, highlights from 2020 include:

• China positive clinical study results reported
• Canada commercial launch of VASCEPA initiated (just prior to slowdown from COVID-19)
• Canada reimbursement levels for VASCEPA established within six months of product regulatory approval to facilitate treating patients with established cardiovascular disease

ROW outlook includes:

• Large at-risk patient opportunities
  • In China 290 million people are reported to have cardiovascular disease, a number which has been increasing rapidly in recent years, including approximately 52 million reported to have high TG levels, a substantial portion of whom might be able to benefit from VASCEPA
• Plans to submit application for regulatory approval through Amarin’s commercial partner in the People’s Republic of China
• Anticipate inclusion of VASCEPA in the treatment guidelines in Chinese medical societies
• Pursue opportunities for VASCEPA in untapped countries after approval and market access in Europe is secured, with such approval and market access expected to enhance ROW positioning

R&D and Medical Advancement

R&D and medical advancement highlights from 2020 include:

• EVAPORATE exploratory study results, as previously reported, reported 17% reduction in plaque volume in patients with coronary atherosclerosis treated with VASCEPA
• Numerous other studies presented in support of the potential unique mechanism of action of VASCEPA
  • In aggregate, Amarin supported over 40 scientific publications and presentations in 2020
• CardioLink-19 exploratory study results, as previously reported, evaluated a higher initial dose of VASCEPA and suggested VASCEPA could potentially have utility as a therapeutic option for mitigating COVID-19 effects in an out-patient setting
  • This pilot study was rapidly commenced and completed with results that exceeded expectations
  • Additional COVID-19 investigational studies of VASCEPA were also commenced in 2020
• Witnessed an increase to twelve (12) the number of medical societies globally that now include icosapent ethyl in their guidelines or have otherwise recommended its use

R&D and medical outlook includes:

• Supporting approval of VASCEPA in Europe and regulatory review processes initiated by Amarin’s commercial partner in the People’s Republic of China
• Supporting cost-effectiveness studies and market access for VASCEPA wherever it is approved
• Support completion of COVID-19 investigational studies and, based on the results, decide on appropriate next steps
• Continue to study and differentiate the unique clinical and biological effects of VASCEPA
• In concert with Amarin’s business development and other efforts, prioritize and execute on potential opportunities to expand indications for VASCEPA or develop new products

Financial Resources

Amarin reiterates that it believes its current cash resources are adequate to support the European launch and its planned operations and priorities in the United States and globally. Such guidance included anticipated resources likely needed to further expand its VASCEPA supply capacity in anticipation of launches of VASCEPA in Europe, China and other countries as well as the opportunity to continue to grow prescription levels in the United States after COVID-19 recedes, continuing the launch of VASCEPA for P-CVR as commenced in 2020.

Currently, Amarin anticipates 2021 operating expenses of approximately $550 million to $600 million which represents an increase of approximately 10% to 20%, compared with 2020 levels. Included in these anticipated expenses are increased costs associated with Amarin’s commercial launch preparations and initial launch in Europe as well as continued U.S. promotional activities, including increased face to face interactions between Amarin’s sales professionals and health care providers and direct-to-consumer advertising in the U.S. after the impact of COVID-19 becomes less pronounced and at-risk patients begin returning to their doctors for non-urgent medical care. With continued investment in consumer and in-person marketing, Amarin expects VASCEPA revenue growth in the U.S. As described above, these spending levels may vary from quarter to quarter. Further these operating expense levels assume substantial societal recovery in 2021 from COVID-19 and the continued limited availability of supply to the generic companies. Amarin will re-evaluate its planned spend in 2021 if any of these assumptions change.

More Information to Follow

Amarin expects to provide further details regarding its 2020 results and perspective regarding its future outlook in the company’s annual report on Form 10-K.

About Amarin

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA^® (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. VASCEPA is not yet approved and available in any other countries. Amarin, on its own or together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, Europe and the Middle East. For more information about Amarin, visit www.amarincorp.com.

About Cardiovascular Risk

Cardiovascular disease is an enormous and growing public burden globally. In the United States alone there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds), in the United States. Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. Cardiovascular disease results in 859,000 deaths per year in the United States.¹ In aggregate, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, one every 13 seconds in the United States alone.

Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.² Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.^3,4,5

About REDUCE-IT^®

REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).

REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.⁶ The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.⁷ The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.⁸ These and other publications can be found in the R&D section on the company’s website at www.amarincorp.com.

About VASCEPA^® (icosapent ethyl) Capsules

VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million times. VASCEPA is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019.

Indications and Limitation of Use

VASCEPA is indicated:

• As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
  • established cardiovascular disease or
  • diabetes mellitus and two or more additional risk factors for cardiovascular disease.
• As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information

• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.
• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.
• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
• Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below:

Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with

Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT

	VASCEPA		Placebo		VASCEPA vs Placebo
	N = 4089 n (%)	Incidence Rate (per 100 patient years)	N = 4090 n (%)	Incidence Rate (per 100 patient years)	Hazard Ratio (95% CI)
Primary composite endpoint
Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE)	705 (17.2)	4.3	901 (22.0)	5.7	0.75 (0.68, 0.83)
Key secondary composite endpoint
Cardiovascular death, myocardial infarction, stroke (3-point MACE)	459 (11.2)	2.7	606 (14.8)	3.7	0.74 (0.65, 0.83)
Other secondary endpoints
Fatal or non-fatal myocardial infarction	250 (6.1)	1.5	355 (8.7)	2.1	0.69 (0.58, 0.81)
Emergent or urgent coronary revascularization	216 (5.3)	1.3	321 (7.8)	1.9	0.65 (0.55, 0.78)
Cardiovascular death [1]	174 (4.3)	1.0	213 (5.2)	1.2	0.80 (0.66, 0.98)
Hospitalization for unstable angina [2]	108 (2.6)	0.6	157 (3.8)	0.9	0.68 (0.53, 0.87)
Fatal or non-fatal stroke	98 (2.4)	0.6	134 (3.3)	0.8	0.72 (0.55, 0.93)
[1] Includes adjudicated cardiovascular deaths and deaths of undetermined causality. [2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization.

FULL VASCEPA

PRESCRIBING INFORMATION

CAN BE FOUND AT WWW.VASCEPA.COM.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding revenue and prescription growth, the impacts of COVID-19, including its future trajectory and effects on non-urgent medical care, the impacts of generic competition, including expected levels of generic supply, changes to U.S. commercial operations, including to spending and promotional levels, plans for commercial and international expansion, including the timing and outcome of regulatory approvals, market access negotiations and commercial launch, R&D and medical outlook, including the timing and results of future studies, market access efforts and indication expansion opportunities, the adequacy of its current cash resources and its 2021 operating expenses. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Amarin’s ability to effectively commercialize VASCEPA will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for VASCEPA through education, marketing and sales activities, to achieve broad market acceptance of VASCEPA, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of VASCEPA and to secure and maintain patent protection for VASCEPA. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated with the COVID-19 pandemic and generic competition; factors outside of our control may prevent VASCEPA from achieving market acceptance and commercial success; the commercial value of VASCEPA outside the United States may be smaller than we anticipate; uncertainties associated generally with research and development, clinical trials and related regulatory approvals; and sales may not meet expectations and related costs may increase beyond expectations. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.

Availability of Other Information About Amarin

Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Amarin Contact Information

Investor Inquiries:

Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
[email protected] (investor inquiries)

Solebury Trout
[email protected]

Media Inquiries:

Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
[email protected] (media inquiries)

________________________________
1		American Heart Association. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139–e596.
2		Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
3		Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.
4		Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.
5		Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease – New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.
6		Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148.
7		Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.
8		Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159-1161.